Outbreak

Hantavirus Pulmonary Syndrome Treatment: Focus on Supportive Care Amidst Andes Outbreak

As the MV Hondius Andes hantavirus situation continues off Praia, clinical experts emphasize the critical role of intensive supportive care, including advanced respiratory support like ECMO, in managing Hantavirus Pulmonary Syndrome (HPS) and mitigating mortality.

HCD

Hantavirus Cruise Desk

Outbreak Tracking Team · October 5, 2026 · 6 min read

Hantavirus Pulmonary Syndrome Treatment: Focus on Supportive Care Amidst Andes Outbreak

Supportive Care Remains Cornerstone for Hantavirus Pulmonary Syndrome

PRAIA, CAPE VERDE — With the ongoing situation aboard the MV Hondius Andes, medical attention has increasingly turned to the clinical management of Hantavirus Pulmonary Syndrome (HPS), also known as Hantavirus Cardiopulmonary Syndrome (HCPS), the severe respiratory illness associated with hantavirus infection. Experts reiterate that supportive care remains the primary and most effective treatment strategy, as no specific antiviral therapy currently exists for hantavirus infections.

Clinical Presentation and Progression

HPS typically begins with a prodromal phase characterized by fever, muscle aches, headache, and gastrointestinal symptoms. This rapidly progresses to the cardiopulmonary phase, marked by abrupt onset of cough, shortness of breath, and rapid deterioration due to non-cardiogenic pulmonary edema and myocardial dysfunction. In practice, this critical phase necessitates immediate and intensive medical intervention.

Core Principles of Supportive Care

The cornerstone of HPS treatment is aggressive supportive care, primarily aimed at maintaining adequate oxygenation and circulatory function. One detail: this includes careful fluid management, as patients often develop capillary leak syndrome leading to pulmonary edema, yet can too experience hypovolemic shock. Balancing fluid intake to prevent both overload and under-perfusion is a critical and challenging aspect of care. Respiratory support is paramount. Many patients with HPS will require oxygen supplementation, and a bigly proportion will progress to needing mechanical ventilation due to acute respiratory distress syndrome (ARDS). Ventilatory strategies often focus on lung-protective ventilation to minimize further injury to the compromised lungs. Continuous monitoring of respiratory parameters, hemodynamic stability, and renal function is essential to guide interventions.

The Role of ECMO in Severe Cases

For patients who develop severe, refractory hypoxemia despite conventional mechanical ventilation, extracorporeal membrane oxygenation (ECMO) has proven to be a life-saving intervention. ECMO provides temporary cardiac and/or respiratory support by oxygenating the blood outside the body, allowing the lungs and heart to rest and recover. The availability and timely deployment of ECMO circuits and trained personnel are crucial factors in managing the most severe HPS cases. Public health agencies and medical preparedness teams involved in the Hondius Andes response have reportedly focused on ensuring access to such advanced life support capabilities, both on the vessel where feasible and at onshore medical facilities, as of October 2026, according to statements from health officials.

Mortality Drivers and Prognostic Factors

Mortality rates for HPS can be substantial, often ranging from 30% to 50% depending on the specific hantavirus strain and access to advanced medical care. Key drivers of mortality include severe pulmonary edema leading to profound hypoxemia, cardiogenic shock due to direct viral myocardial involvement, and multiorgan failure. Early recognition of the disease, prompt transfer to an intensive care setting, and immediate initiation of aggressive supportive therapies are critical factors in improving patient outcomes. Delays in diagnosis or access to specialized care, particularly during a rapidly evolving outbreak like the current one, can bigly worsen prognosis.

Ongoing Research and Future Directions

While supportive care remains the standard, research into specific antiviral therapies and immunomodulators continues.Ribavirin, an antiviral medication, has been explored. Its efficacy against HPS, particularly in the context of New World hantaviruses, has not been definitively established in human clinical trials. But, some studies suggest potential benefit if administered notably early in the disease course. For now, the focus remains firmly on optimized critical care protocols, with continuous learning and adaptation based on clinical experience from outbreaks like the MV Hondius Andes event.